Episode 168 - January 9, 2026

What It Covers

Biotech Hangout opens 2026 with analysis of strong sector momentum driven by M&A activity, successful IPOs, and positive market sentiment. The XBI trades at 2125, matching November 2021 levels. Discussion covers Revolution Medicine takeover rumors, Actis Pharmaceuticals IPO raising $318 million, emerging obesity mechanisms beyond GLP-1s, and policy concerns including CDC vaccine schedule changes and CMS pricing demonstrations.

Key Questions Answered

• •M&A Market Dynamics: Revolution Medicine attracts competing bids from AbbVie and Merck at $28-32 billion valuation, representing premium multiples versus historical oncology deals like Loxo and Array. This follows AstraZeneca's $100 million upfront deal with China's Jacobio for a pan-RAS inhibitor and Lilly's VTYX acquisition. Multiple pan-RAS programs validate the target class, with RevMed's phase 3 pancreatic cancer asset potentially reaching market within two years in high unmet need indication.
• •IPO Window Reopens: Actis Pharmaceuticals prices at $18 versus $16-18 range, raises $318 million including $100 million from partner Lilly, and opens at $27 with 10x oversubscription. The radioligand therapy company uses novel mini-protein discovery platform rather than existing peptides, targeting NECTIN-4 initially. Last private raise was $175 million series B in September 2024 from RA Capital, RTW, Janus Henderson, with additional backing from T. Rowe Price, Avidity, Lilly, Bristol Myers, and Merck ventures.
• •Follow-On Financing Surge: Companies pull secondary offerings earlier than traditional post-JPMorgan timing, with all deals upsizing and trading double-digit percentages above offer price. Crynetics raises capital following Pulsenify launch exceeding consensus with 200 enrollment forms in first full quarter for niche indication, plus positive congenital adrenal hyperplasia phase 2 data showing glucocorticoid reduction. Strong follow-on performance indicates robust capital availability and investor enthusiasm entering 2026.
• •Next-Generation TYK2 Inhibitors: Alumis demonstrates envudacitinib achieves PASI 90 in over 50% of psoriasis patients and PASI 100 in 30-40%, matching J&J's oral IL-23 inhibitor icotrokinra and rivaling biologic efficacy. Takeda's TYK279 shows similar results, reframing oral small molecule potential after Bristol's Sotyktu commercial disappointment. Second-generation TYK2s avoid first-generation liabilities while expanding into psoriatic arthritis, ulcerative colitis, and SLE, with Bristol and Alumis both reporting phase 3 SLE data in 2026.
• •Obesity Beyond GLP-1: Arrowhead raises upsized $625 million following ARO-INHBE phase 2 data showing strong efficacy in diabetic obese patients when combined with tirzepatide, despite minimal monotherapy effect in non-diabetic obesity. The siRNA approach targets visceral adipose tissue and liver fat content through novel pathway distinct from GLP-1 mechanisms. Wave Life Sciences pursues similar strategy. Regulatory pathway remains unclear given combination-dependent efficacy, but market validates novel mechanisms addressing muscle preservation and metabolic health beyond weight loss alone.
• •Policy Overhang Persists: CDC removes six vaccines from recommended pediatric schedule without ACIP discussion, including rotavirus, COVID, influenza, meningococcal, hepatitis A, and reduces HPV to single dose. Insurance coverage remains unchanged, limiting immediate commercial impact. CMS most-favored-nation demonstration announcement generates minimal market reaction, suggesting investors either dismiss implementation probability or underestimate impact. Market resilience to policy headlines creates downside risk if significant pricing reform materializes, as investor desensitization may delay appropriate risk assessment.